News
Eric Green, M.D., Ph.D., formerly the NHGRI director, has been awarded by Fierce Pharma as a Fierce 50 Innovation Honoree. The Fierce 50 is designed to honor the 50 most influential leaders and organizations shaping the future of biopharma, healthcare, and life sciences. The Fierce editorial team
The National Cancer Institute’s (NCI) Drug Synthesis and Chemistry Branch created a potential therapeutic for various types of cancers including colon cancer and leukemia by synthesizing a fluorinated cytidine. They showed that incorporating a fluorine atom into the chemical structure of cytidine
Register for your spot at the National Cancer Institute (NCI) and Frederick National Lab’s (FNL) 2021 Technology Showcase. This event provides potential partners the opportunity to attend presentations on federal technologies ready for commercialization and/or collaboration, watch panel sessions
NCI investigators have developed a solution to address the challenges that nucleic acid based therapeutics face of non-specific delivery and degradation of the nanoparticles. NCI’s solution is an inducible activation nucleic acid hybrid switch. The use of nucleic acid logic elements in these